Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
2007 Release
December 27, 2007
U.S. District Court Decision about Eisai's Legal Action over Aricept ODT® ANDA Filing
December 25, 2007
Eisai Introduces New Aricept® Dose Formulations for Treatment of Severe Alzheimer's Disease in Japan
December 18, 2007
December 10, 2007
EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION
December 6, 2007
Eisai Celebrates Ground-Breaking Ceremony For New Manufacturing and Research Base in India
December 4, 2007
November 29, 2007
Eisai Submits NDA Application of KES524 for Obesity Management in Japan
October 30, 2007
Eisai Announces Change in Regulatory Submission Strategy of E2007 for Parkinson's Disease
September 28, 2007
Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
September 28, 2007
September 25, 2007
September 5, 2007
August 24, 2007
August 23, 2007
August 23, 2007
August 11, 2007
UK High Court Ordered NICE To Amend A Guidance for Alzheimer's Disease
August 10, 2007
UK High Court Ruled NICE Guidance for Alzheimer's Disease Discriminatory
July 31, 2007
July 27, 2007
July 27, 2007
Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment
July 17, 2007
July 11, 2007
July 9, 2007
Notice on Details of Stock Options (New Share Acquisition Rights) to be Allocated
June 26, 2007
Tambocor® (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter
June 22, 2007
Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 18, 2007
June 15, 2007
A ONCE-WEEKLY ANTIOSTEOPOROTIC AGENT “ACTONEL® 17.5 mg TABLETS” IS LAUNCHED.
June 12, 2007
May 15, 2007
Eisai Signs Exclusive Agreement to Commercialize NeuroBloc® for Europe
May 15, 2007
Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand
May 15, 2007
May 15, 2007
Basic Principle and Policies concerning Reduction of Minimum Trading Lots for Shares
May 12, 2007
May 7, 2007
May 7, 2007
April 26, 2007
April 18, 2007
A ONCE-WEEKLY FORMULATION OF RISEDRONATE SODIUM HYDRATE, AN ANTIOSTEOPOROTIC AGENT, WAS APPROVED.
April 17, 2007
April 13, 2007
March 26, 2007
Asahi Kasei Pharma Corporation and °®¶¹´«Ã½. Signed License Agreement for Vasodilator Eril® in Korea
March 22, 2007
March 5, 2007
Eisai Establishes New Manufacturing Subsidiary in United Kingdom
March 1, 2007
February 2, 2007
January 30, 2007
January 22, 2007
Inovelon® recieves Marketing Authorization Approval from European Commission